374 related articles for article (PubMed ID: 30367185)
41. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
42. Predicting epidermal growth factor receptor mutations in non-small cell lung cancer through dual-layer spectral CT: a prospective study.
Li F; Qi L; Cheng S; Liu J; Chen J; Cui S; Dong S; Wang J
Insights Imaging; 2024 Apr; 15(1):109. PubMed ID: 38679659
[TBL] [Abstract][Full Text] [Related]
43. A new predictive scoring system based on clinical data and computed tomography features for diagnosing
Cao Y; Xu H
Curr Oncol; 2018 Apr; 25(2):e132-e138. PubMed ID: 29719437
[TBL] [Abstract][Full Text] [Related]
44. Prognostic and predictive role of epidermal growth factor receptor mutation in recurrent pulmonary adenocarcinoma after curative resection.
Jeon JH; Kang CH; Kim HS; Seong YW; Park IK; Kim YT
Eur J Cardiothorac Surg; 2015 Mar; 47(3):556-62. PubMed ID: 24760387
[TBL] [Abstract][Full Text] [Related]
45. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
46. The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas.
Cho J; Choi SM; Lee J; Lee CH; Lee SM; Yim JJ; Chung DH; Yoo CG; Kim YW; Han SK; Park YS
PLoS One; 2016; 11(11):e0166821. PubMed ID: 27861565
[TBL] [Abstract][Full Text] [Related]
47. [Relationship between EGFR, ALK Gene Mutation and Imaging
and Pathological Features in Invasive Lung Adenocarcinoma].
Yang H; Liu Z; Wang H; Chen L; Wang J; Wen W; Xu X; Zhu Q
Zhongguo Fei Ai Za Zhi; 2022 Mar; 25(3):147-155. PubMed ID: 35340157
[TBL] [Abstract][Full Text] [Related]
48. Relation of EGFR Mutation Status to Metabolic Activity in Localized Lung Adenocarcinoma and Its Influence on the Use of FDG PET/CT Parameters in Prognosis.
Kim YI; Paeng JC; Park YS; Cheon GJ; Lee DS; Chung JK; Kang KW
AJR Am J Roentgenol; 2018 Jun; 210(6):1346-1351. PubMed ID: 29547059
[TBL] [Abstract][Full Text] [Related]
49. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
[TBL] [Abstract][Full Text] [Related]
50. Combination of
Li S; Li Y; Zhao M; Wang P; Xin J
Korean J Radiol; 2022 Sep; 23(9):921-930. PubMed ID: 36047542
[TBL] [Abstract][Full Text] [Related]
51. Differentiating malignant and benign necrotic lung lesions using kVp-switching dual-energy spectral computed tomography.
Li Q; Fan X; Luo TY; Lv FJ; Huang XT
BMC Med Imaging; 2021 May; 21(1):81. PubMed ID: 33985454
[TBL] [Abstract][Full Text] [Related]
52. Dual-energy dynamic CT of lung adenocarcinoma: correlation of iodine uptake with tumor gene expression.
Yanagawa M; Morii E; Hata A; Fujiwara M; Gyobu T; Ueda K; Honda O; Tomiyama N
Eur J Radiol; 2016 Aug; 85(8):1407-13. PubMed ID: 27423680
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Value of Baseline 18F-FDG PET/CT Functional Parameters in Patients with Advanced Lung Adenocarcinoma Stratified by EGFR Mutation Status.
Wang D; Zhang M; Gao X; Yu L
PLoS One; 2016; 11(6):e0158307. PubMed ID: 27336755
[TBL] [Abstract][Full Text] [Related]
54. Computed tomography characteristics of lung adenocarcinomas with epidermal growth factor receptor mutation: A propensity score matching study.
Suh YJ; Lee HJ; Kim YJ; Kim KG; Kim H; Jeon YK; Kim YT
Lung Cancer; 2018 Sep; 123():52-59. PubMed ID: 30089595
[TBL] [Abstract][Full Text] [Related]
55. Comparative analysis of clinicoradiologic characteristics of lung adenocarcinomas with ALK rearrangements or EGFR mutations.
Zhou JY; Zheng J; Yu ZF; Xiao WB; Zhao J; Sun K; Wang B; Chen X; Jiang LN; Ding W; Zhou JY
Eur Radiol; 2015 May; 25(5):1257-66. PubMed ID: 25577516
[TBL] [Abstract][Full Text] [Related]
56. Impact of Pulmonary Tuberculosis on the EGFR Mutational Status and Clinical Outcome in Patients with Lung Adenocarcinoma.
Hwang IK; Paik SS; Lee SH
Cancer Res Treat; 2019 Jan; 51(1):158-168. PubMed ID: 29621876
[TBL] [Abstract][Full Text] [Related]
57. Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.
Sánchez-Font A; Chalela R; Martín-Ontiyuelo C; Albero-González R; Dalmases A; Longarón R; Alonso-Espinaco V; Curull V; Bellosillo B; Pijuan L
Cancer Cytopathol; 2018 Oct; 126(10):860-871. PubMed ID: 30291816
[TBL] [Abstract][Full Text] [Related]
58. FDG PET texture indices as imaging biomarkers for epidermal growth factor receptor mutation status in lung adenocarcinoma.
Ishimura M; Norikane T; Mitamura K; Yamamoto Y; Manabe Y; Murao M; Murota M; Kanaji N; Nishiyama Y
Sci Rep; 2023 Apr; 13(1):6742. PubMed ID: 37185611
[TBL] [Abstract][Full Text] [Related]
59. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
60. Relationships between EGFR mutation status of lung cancer and preoperative factors - are they predictive?
Usuda K; Sagawa M; Motono N; Ueno M; Tanaka M; Machida Y; Matoba M; Taniguchi M; Tonami H; Ueda Y; Sakuma T
Asian Pac J Cancer Prev; 2014; 15(2):657-62. PubMed ID: 24568474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
